Company: RNAC
Filing Date: 2025-10-21
Form Type: 8-K
Source: 0001453687-25-000106
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-10-21
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2025, Cartesian Therapeutics, Inc. (the “ Company”) eliminated the position of Chief Scientific Officer and delivered a notice of termination of employment without cause to Christopher Jewell, Ph. D., who currently serves as the Company’s Chief Scientific Officer, each effective as of November 14, 2025. On October 20, 2025, the Company and Dr. Jewell entered into a separation agreement and release (the “ Separation Agreement”).

Pursuant to the Separation Agreement, Dr. Jewell agreed to release the Releasees (as such term is defined in the Separation Agreement) from any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Dr. Jewell may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including November 14, 2025, in consideration for receipt from the Company of the severance payments and benefits described in the employment agreement, dated March 26, 2024, by and between the Company and Dr. Jewell (the “ Jewell Employment Agreement”), including payment of 12-months’ salary and eligibility for a pro-rated bonus. The Jewell Employment Agreement was filed as Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and is incorporated herein by reference.

A copy of the Separation Agreement is expected to be filed with the Company’s Annual Report on Form 10-K for the year ending December 31, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  CARTESIAN THERAPEUTICS, INC.                                             
  By:                               /s/ Carsten Brunn, Ph. D.              
                                    Carsten Brunn, Ph. D.                  
                                    President and Chief Executive Officer